
Bristol-Myers Squibb Co.
BMYBristol-Myers Squibb Co. is a global pharmaceutical company focused on discovering, developing, and delivering innovative medicines in areas such as oncology, immunology, cardiovascular, and neuroscience. Founded in 1858, it has a long history of advancing health through its diverse portfolio of prescription therapies.
Dividend History
Investors can expect a dividend payout of $0.63 per share, scheduled to be distributed in 16 days on August 3, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 3, 2026 | $0.63 | 2026-07-02 | 2026-07-02 |
| May 1, 2026 | $0.63 | 2026-04-02 | 2026-04-02 |
| February 2, 2026 | $0.63 | 2026-01-02 | 2026-01-02 |
| November 3, 2025 | $0.62 | 2025-10-03 | 2025-10-03 |
| August 1, 2025 | $0.62 | 2025-07-03 | 2025-07-03 |
Dividends Summary
- Consistent Payer: Bristol-Myers Squibb Co. has rewarded shareholders with 91 dividend payments over the past 22 years.
- Total Returned Value: Investors who held BMY shares during this period received a total of $36.53 per share in dividend income.
- Latest Payout: The most recent dividend of $0.63/share was paid 78 days ago, on May 1, 2026.
- Yield & Schedule: BMY currently pays dividends quarterly with an annual yield of 4.13%.
- Dividend Growth: Since 2004, the dividend payout has grown by 125.0%, from $0.28 to $0.63.
- Dividend Reliability: BMY has maintained or increased its dividend for 91 consecutive payments.
Company News
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the h...
Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (...
The cancer metabolism-based therapeutics market is projected to grow from $3.7 billion in 2026 to $26.3 billion by 2035, driven by precision medicine approaches and rising cancer prevalence. The market includes approximately 250 therapeutic programs targeting cancer metabolism vulnerabilities, with North America expected to hold over 45% market s...
The article compares two major healthcare stocks: Bristol Myers Squibb (BMY), a specialized biopharmaceutical company focused on oncology and immunology, and Johnson & Johnson (JNJ), a diversified healthcare giant with innovative medicine and medical device segments. While BMY trades at a significant valuation discount with a higher dividend yiel...









